Expression Level of SIRT2 in Cervical Cancer Tissue and Its Clinical Significance

CHEN Jing, WANG Hong-jing

Abstract

To investigate the expression level of silencing information regulatory 2 (SIRT2) in cervical cancer and CIN tissues and its clinical significance.  Methods   Immunohistochemistry was carried out to examine the expression of SIRT2 in 262 cases of cervical cancer tissues, 75 cases of precancerous lesions and 75 cases of normal cervical tissues, and the clinical implications of SIRT2 was further analyzed. The protein expression level of SIRT2 in 40 cervical cancer fresh tissue samples and 20 normal cervical tissue samples was detected by Western blot. shRNA-SIRT2 virus was transfected into HeLa cells to obtain the SIRT2-down-regulated HeLa cells. And the influence of down-regulation of SIRT2 on cell proliferation and migration was investigated by MTT and Scratch test.  Results   Immunohistochemical results showed that SIRT2 protein expression level gradually increased in cervical cancer, CIN and normal cervix tissues (P < 0.001). Western blot confirmed that SIRT2 expression level was higher in cervical cancer tissues than in normal cervix tissues (P < 0.001). The expression level of SIRT2 in cervical cancer was correlated with some factors, such as lymph node metastasis, histological type, clinical staging and HPV infection (P < 0.05). At the same time, it was independent of some factors including age, differentiation degree, pelvic metastasis, whether involving the cervical interstitial and the involvement depth and whether involving the neck junction and vaginal ends (P>0.05). Mortality in SIRT2 high expression patient group was higher than that of SIRT2 low expression patient group (P < 0.05). shRNA interference technique could effectively inhibit the expression level of SIRT2 in HeLa cells (P < 0.05). MTT assay and Scratch test indicated that down-regulation of SIRT2 expression inhibited the proliferation and migration of HeLa cells (P < 0.05).  Conclusion   SIRT2 may play a promoting role in the progress of cervical cancer, and SIRT2 may be related to the development of malignant degree of cervical cancer, and the inhibition of SIRT2 expression may be a potential therapeutic target for cervical cancer.

 

Keywords: SIRT2, Cervical cancer, Immunohistochemistry, Clinicopathological features, Survival analysis

 

Full Text:

PDF


References


FERLAYJ. SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. J Int Cancer,2015, 136(5);359-386.

QMICHOUZ, KHYATTI M, BERRAHO M. et al. Anaysis of mutations in the E6 oncogene of human papillomavius 16 in cervical cancer isolares from Moroccan women. BMC Infect Dis, 2013, 13: 378 [ 2019-05-17 ]. https;//doi. org/10. 1186/1471-2334-13-378.

LI N.FRANCESCHI S, HOWELL-JONES R,et al. Human papillomavirus type distribution in 30 818 invasive cervical cancers worldwide; variation by geographical region, histological type and year of publication. Int Cancer,2011,128 (4):927-935.

TJALMA W A, VAN WAES T R.VAN DEN EEDEN L E, et al. Role of human papillomavirus int he carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract Res Clin Obstet Gynaecol,2005,19(4):469-483.

CUSCHIERI К S, WHITLEY M J, CUBIE H A. Human papillomavirus type specific DNA and RNA persistence; implications for cervical disease progression and monitoring. J Med Virol. 2004 ,73(1); 65-70.

THOMAS D, RAY R M, QIN Q. Risk factors for progression of squamous cell cervical carcinoma insitu to invasive cervical cancer; result of a multiple study. Cancer Cause Contro,2002,13(7):683-690.

CHEN J, CHAN A W. TO К F,et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3j3,/(3-cateninsignaling. Hepatology, 2013, 57 (6):2287-2298.

CONSTANTINOU P. TISCHKOWITZ M. Genetics of gynaecological cancers. Best Pract Res Clin Obstet Gynaecol. 2017,42: 114-124[2019-05-17]. https;//doi. org/10. 1016/j. bpobgyn. 2017. 01. 004Get rights and content.

SEBASTIAN С, ZWAANS В M. SILBERMAN D M. et al. The histone deacetylase SIRT6 is a tumor suppressor that control cancer metabolism. Cell.2012,151 (6): 1185-1199. CHA Y I. KIM H S. Emerging role of sirtuins on tumorigenesis: possible link between aging and cancer. BMB Reports,2013,46(9);429-438.

KOZAKOT, SUZUKI T, YOSHIMITSU M, et al. Anticancer agents targeted to sirtuins. Molecules, 2011, 19 (12):20295-20313.

MCGLYNN L M, ZINO S, MACDONALD A I, et al. SIRT2: tumour suppressor or tumour promoter in operable breast cancer. Eur J Cancer,2014 ,50(2); 290-301.

SCHWARTZ S М. WEISS N S. Increased incidence of adenocaarcinoma of the cervix in young women in the United States. Am J Epidemiol. 1986,124(6); 1045-1047.

YAMAKAWA Y. FORSLUND O. TESHIMA H. et al. Human papillomavims DNA in adenocarcinoma and adenosquarnous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR). Gynecol Oncol. 1994, 53 (2):190-195.

GAO G, SMITH DI. Human papillomavirus and the development of different cancers. Cytogenet Genome Res, 2016,150(3/4):185-193.

LI Y, MATSUMORI H. NAKAYAmI Y. et al. S1RT2 down-regulation in HeLa can induce p53 accumulation via p38 МАРК activation-dependepent 300 decrease, eventually leading to apoptosis. Genes Cells,2011,16( 1);34-45.

JING H. HU J. HE B, et al. A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity. Cancer Cell,2016,29(3):297-310.


Refbacks

  • There are currently no refbacks.